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Racial and ethnic disparities have been reported in clinical trial/research participation, utilization of autol-
ogous and allogeneic blood and marrow transplantation (BMT), and availability of allogeneic donors. We
performed a population-based cohort study to investigate adult hematologic malignancy referrals to a US
tertiary cancer center, utilization of BMT, and participation in clinical trial, survey, and biospecimen research
by race. US Census Data and the New York State Public Access Cancer Epidemiology Database identiﬁed the
racial distribution of the general population and new hematologic malignancy cases in the primary catchment
area. From 2005 to 2011, 1106 patients aged 18 to 75 years were referred for BMT consultation; although the
rate of BMT among hematologic malignancy referrals did not differ by race, the reasons for not receiving a
BMT did. Participation in biospecimen research did not vary by race; however, African Americans and other
minorities were signiﬁcantly less likely to participate in survey research than European Americans. Although
rates of hematologic malignancy referrals and use of BMT for minorities appear to be low (<10%), they closely
reﬂect the race distribution of all hematologic malignancy cases and the western New York population.
African Americans are equally likely as other races to participate in biospecimen banking, but further study is
needed to understand reasons for lower participation in survey research.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous and allogeneic blood and marrow trans-
plantation (BMT) are complex, intensive treatments usually
performed in tertiary care centers. Patients are initially
referred for BMT consultation and subsequently undergo a
comprehensive medical workup, psychological evaluation
including compliance, social work evaluation including
caregiver support, screening for insurance and ﬁnancial
support, and, if applicable, an allogeneic donor search.
Patients with comorbidities can still be eligible for a BMT if
the comorbidities are controlled [1]; comorbidities include
coronary artery disease, prior myocardial infarction,edgments on page 1493.
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ty for Blood and Marrow Transplantation.depression, diabetes, and prior cancer. During the BMT
evaluation process, which can take weeks to months, pa-
tients and/or their physicians may decide the patient is not a
suitable candidate and it is not in the patient’s best interest
to have a BMT.
The under-utilization of both autologous and allogeneic
BMT by race and gender was previously reported on a na-
tional basis [2]. A recent analysis of the allogeneic donor pool
within the National Marrow Donor Program demonstrated
thatmost BMTcandidates will have a suitable 7/8 or 8/8 HLA-
matched allogeneic donor in the registry but an optimal 8/8
HLA-matched donor is more likely to be found for European
American (EA) patients (75% chance) than for African
Americans (AAs) (16% to 19% chance) or other minorities
(27% to 52% chance) [3]. Autologous BMT does not require a
donor, has fewer side effects than an allogeneic BMT, and
requires less follow-up and resources than an allogeneic
BMT. However, autologous BMT for multiple myeloma (MM)
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the incidence of MM is twice as common in AAs as in EAs
[2,4]. This suggests that disparities in use of BMT by race
cannot be attributed solely to donor availability and may be
due to socioeconomic factors.
We investigated population-based rates of hematologic
malignancy cases, referrals for BMT consultation, utilization
of BMT as therapy, and participation in clinical trial, survey,
and biospecimen research by race in our US center. We
examined demographic factors that might inﬂuence referral
for BMT consultation and that may impede a patient’s ability
to undergo BMT. Identiﬁcation of modiﬁable factors could
lead to interventions to decrease disparities in BMT referrals
and increase utilization of BMT byminorities. We also sought
to investigate the rate of participation in clinical research by
race, because studies to improve disparities in outcomes or
utilization of BMT will be compromised by low participation
rates in minority populations.METHODS
Study Population
We conducted a population-based analysis of the average annual new
hematologic cancer cases (acute and chronic leukemia, Hodgkin [HL] and
non-Hodgkin lymphoma [NHL], and MM) diagnosed from 2005 to 2009 by
race and age using the New York State (NYS) Department of Health (DOH)
Cancer Registry. NYS Public Health Law, Article 24, Title 1, Section 2401
requires all NYS physicians, dentists, laboratories, and other healthcare
providers to report every case of cancer or other malignant disease to the
NYS DOH Cancer Registry [5]. The NYS Public Access Cancer Epidemiology
Data (NYSPACED) can be used to analyze cancer incidence and mortality
data reported to the NYS DOH Cancer Registry [6].
Roswell Park Cancer Institute (RPCI) is the only National Cancer Insti-
tuteedesignated Comprehensive Cancer Center in NYS outside of New York
City, with the nearest cancer hospital about 75 miles away. Therefore, the
main catchment areas for RPCI are the 8 counties (Allegany, Cattaraugus,
Chautauqua, Erie, Genesee, Niagara, Orleans, andWyoming) of western New
York, from which 75% of all RPCI BMT referrals originate. The RPCI BMT
database prospectively collects patient information (demographic, disease,
treatment, and outcomes data) in real time from initial BMT referral until
death or last follow-up. Disposition of BMT referrals includes the following:
(1) the patient had an autologous or allogeneic BMT, (2) the patient did not
have a BMT and the reason why, or (3) the patient is still pending a decision
(currently undergoing workup, searching for a donor, undergoing active
cancer therapy, collecting hematopoietic cells, pending insurance approval,
etc.). The RPCI Clinical Research Services database tracks all research study
participation including consent, enrollment, and study outcomes by race,
age and gender.
The RPCI Data Bank and Biorepository (DBBR) is a comprehensive data
and sample bank containing high-quality pretreatment biological speci-
mens and associated clinical and epidemiologic data [7]. Brieﬂy, all cancer
referrals to RPCI are invited to participate. In addition, patients with benign
diseases and healthy individuals (family/friends of patients and community
volunteers) are also recruited to participate in the DBBR. After consent,
blood samples are collected, and an epidemiologic questionnaire is given to
the patient or healthy individual to complete and return by mail. The
epidemiologic survey has 2 versions, 1 for males and 1 for females, that
contain questions on reproductive history, family and personal history of
cancer, vitamin and supplement use, diet, exercise, smoking history, alcohol
history, medications and other drug use, education, marital status, and
household income.Study Design
To determine the proportions of race and ethnicity in the general pop-
ulation in the 8 counties of western New York (main catchment area), we
used 2010 US census data for people aged 18 to 75 years (based on published
US Census age categories). NYSPACED data from 2005 to 2009 was used to
determine the race and ethnicity of all cases of hematologic malignancies
aged 20 to 74 years (based on published NYSPACED age categories) diag-
nosed in the 8 counties of western New York. The RPCI BMT database
captured all BMT referrals from January 2005 to August 2011. The BMT
referral datawere extended about 20 months after the end of the NYSPACED
data collection period to account for a lag time between diagnosis and
referral. DBBR epidemiologic questionnaire data were available for BMT
referrals who participated.Study Deﬁnitions
Race and ethnicity were based on self-identiﬁcation and self-report for
US Census Data (http://www.census.gov/topics/population/race.html). Race
and ethnicity data for NYSPACED are submitted by the medical provider
reporting to the NYS DOH based on the patient’s medical record [6]. Race
and ethnicity for BMT referrals were documented in the medical record
based on self-report at time of initial registration at RPCI. Adults were
deﬁned as follows: young, 18 to 39 years; middle age, 40 to 64 years; or
Medicare eligible, 65 to 75 years. Patients > 75 years were not eligible for a
BMT at RPCI during this time period. Disease risk was deﬁned as low (ﬁrst
complete remission), intermediate (second or greater complete remission),
or high (not in remission). Smoking status was coded as current, former, or
never. Alcohol consumption was coded as never, social (1 drink a month),
monthly (2 to 3 drinks a month), or weekly (4 to 8 drinks a week). Total
household income was collected and analyzed as <$25,000, $25,000 to
49,999, $50,000 to 74,999, and $75,000. The median of each total house-
hold income category was divided by the total number of individuals within
the household to create a variable estimating the amount of income support
per person within a household. Patients with missing values or “I don’t
know” responses on the DBBR questionnairewere coded in the lowest group
for the following variables: education status (high school or less; n ¼ 7
missing), currently employed (no; n ¼ 4 missing), and marital status (single,
never married; n ¼ 10 missing).
Statistical Analysis
We used NYSPACED to ascertain the average annual cases of leukemia,
HL, NHL, and MM from those aged 20 to 74 years and diagnosed from 2005
to 2009 in the 8 counties of western New York. The proportion of EA and AA
cases were available for Erie County and all of NYS (excluding New York City)
for all ages. The proportion of each race (EA/AA) was applied to the average
annual cases aged 20 to 74 years for Erie County (using Erie County data) and
the remaining 7 western New York counties (using the NYS, excluding New
York City, data). We included BMT referrals over a 6.7-year period, and the
average annual case rate was multiplied by 6.7 to estimate the new incident
cases available for BMT referral.
Univariate comparisons of categorical variables used the Pearson chi-
square test or analysis of variance, as appropriate. Patients pending a deci-
sion regarding BMT were excluded from the analysis (n ¼ 45). Participants
were not excluded from the analysis because of missing responses from the
DBBR questionnaire. AAs (n ¼ 12) and all other minorities (n ¼ 7) were
combined as 1 group and compared with EAs because of the small number
of minority patients. All statistical analyses were performed using SPSS
version 21 (2007, IBM, Armonk, NY). This study was reviewed and approved
by the RPCI Institutional Review Board.
RESULTS
Population-Based Analysis
Based on US Census Data from 2007 to 2011, the adult
population aged 18 to 74 years in the 8 counties of western
New York (the primary catchment area for RPCI) was 90% EA
and 10% minorities (including 9.5% AAs and <1% all other
races/ethnicities) (Table 1). Based on US Census Data in the 8
counties of western New York, 59% of the Hispanic popula-
tion and 48% of the AA population were younger than 30
years compared with 35% of the EA population. Because the
minority populations in western New York are signiﬁcantly
younger than the EA population and younger than the me-
dian age at onset of hematologic malignancies, they have a
low risk for developing hematologic malignancies or a rare
need for BMT. This was conﬁrmed in NYSPACED data
demonstrating slightly less minorities (8% AAs, <1% all other
races/ethnicities) among hematologic malignancy cases than
in the general population.
Source of RPCI BMT Referrals
All referrals of adults to RPCI for potential BMT from 2005
to 2011 who resided in 1 of the 8 counties of western
New York had the same proportion of AAs (8%) and slightly
higher proportion of other races/ethnicities (2%) as the
NYSPACED hematologic malignancy cases (Table 1). The
total BMT referral population, regardless of primary
residence, had slightly less AAs (7%) and slightly more other
Table 2
Characteristics of All Patients Referred for a BMT Consultation at RPCI be-
tween January 2005-August 2011, by Race
European
American
(N ¼ 1000)
n (%)
African
American
(N ¼ 76)
n (%)
Other
(N ¼ 30)
n (%)
P-Value
Gender .03
Female 423 (42) 43 (57) 16 (53)
Male 577 (58) 33 (43) 14 (47)
Age, yr .005
<21 67 (7) 6 (8) 5 (17)
21-39 141 (17) 13 (17) 11 (37)
40-64 620 (62) 47 (62) 11 (37)
65-74 164 (16) 9 (12) 2 (7)
75 8 (1) 1 (1) 1 (3)
Diagnosis .01
Leukemia 359 (40) 26 (34) 14 (47)
NHL 251 (25) 8 (11) 3 (10)
MM 166 (17) 26 (34) 5 (17)
MDS 72 (7) 5 (7) 1 (3)
HL 53 (5) 4 (5) 1 (3)
MPN 29 (3) 1 (1) 2 (7)
Amyloidosis 27 (3) 1 (1) 1 (3)
Solid tumor 25 (3) 1 (1) 2 (7)
Benign hem. disorder 18 (2) 4 (6) 1 (3)
Received BMT .05
Yes - total BMTs 494 (49) 31 (41) 10 (33)
Yes - allo BMT 270 (27) 9 (12) 6 (20)
Yes - auto BMT 224 (22) 22 (29) 4 (13)
No 470 (47) 38 (50) 18 (60)
Pending 36 (4) 7 (9) 2 (7)
Participation in research* <.0001
Yes 430 (43) 13 (17) 6 (20)
No 570 (57) 63 (83) 24 (80)
Other indicates all other races/ethnicities; MDS, myelodysplastic syndrome;
MPN, myeloproliferative neoplasm.
* Includes survey research.
Table 1
Population Based Comparison of Race Distribution among Adults Aged 18-
74 Years Residing in the Main Catchment Area, Hematologic Malignancy
Cases Diagnosed in the Main Catchment Area, BMT Referrals from the Main
Catchment Area, BMTs Performed, Participants in Clinical Trial, Survey and/
or Biospecimen Research
European
American
African
American
Other
US census data 2007-2011,
western New York
90% 9.5% <1%
NYSPACED, 2005-2009 cases of
acute and chronic leukemia,
lymphoma and myeloma,
western New York
91% 8% <1%
Total referrals to RPCI BMT
program, 2005-2011, and
resided in a western
New York county
90% 8% 2%
Total referrals to RPCI BMT
program, 2005-2011,
regardless of residence
90.5% 7% 2.5%
All patients who received a
BMT at RPCI, 2005-2011
92% 6% 2%
Received a BMT at RPCI,
2005-2011, and resided in a
western New York county
91% 7% 2%
Proportion of BMT referrals who
participated in biospecimen
research, 2005-2011*
95% 95% 88%
Proportion of BMT referrals who
participated in survey
research, 2005-2011*
70% 34% 38%
Proportion of BMT referrals
who participated in clinical
trials, 2005-2011
62% 57% 43%
8 counties of western New York State includes: Erie, Niagara, Alleghany,
Chautauqua, Cattaraugus, Cayuga, Genesee, Orleans and Wyoming.
Other: Asian, Native American, Hispanic.
* Proportion of those who were approached and consented.
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malignancy cases. Referrals of western New York cases for
BMT consultation differed by race and type of hematologic
malignancy. The rates of referrals were higher for EAs
compared with AAs for HL (23% versus 15%), NHL (16% versus
7%), and MM (40% versus 31%) but were lower for leukemia
(35% versus 40%).Characteristics of RPCI BMT Referrals
A total of 1106 patients were referred to the RPCI BMT
program between January 2005 and August 2011, including
90.5% EAs, 7% AAs, and 2.5% all other minorities (Table 1).
About 75% of all referrals to the RPCI BMT programwere from
the 8 counties of western New York. The most common di-
agnoses among BMT referrals were leukemia, NHL/HL, and
MM (Table 2). There were more males in the EA referrals
(58%) and more females in the AA (57%) and other minority
(55%) referrals. More than half (62%) of EA and AA BMT re-
ferrals were between the ages of 40 and 64 years, whereas
most of the other minority groups (54%) were younger than
40 years (Table 2).
Overall, 535 patients (48%) received a BMT; however, this
varied by race (Table 2, Figure 1). Of all EA referrals, 49%
received a BMT compared with 41% of all AAs and 33% of all
other minorities. Participation in survey research was highest
among EA referrals (43%), with a small proportion of AAs (17%)
and other minorities (20%) participating in survey research.
Participation in survey research was also higher for patients
who had a BMT (58%) versus those who did not (23%).The reasons for not receiving a BMT are summarized in
Table 3 and varied by race. Among EAs, the most common
reasons for not receiving a BMT were patient decision/
treatment reluctance (20%), stable disease not severe enough
to warrant BMT (20%), death before BMT (19%), and disease
progression (14%). Among AAs, the most common reason for
not receiving a BMT was comorbidities/physician decision
(29%), followed by death before BMT (16%), patient decision/
treatment reluctance (13%), stable disease not severe enough
to warrant BMT (13%), and transferred care to another center
(13%). Other minorities’ most common reasons for not
receiving a BMT were stable disease not severe enough to
warrant BMT (22%), transferred care to another center (22%),
death before BMT (17%), comorbidities/physician decision
(11%), and disease progression (11%). Importantly, in all races
failure to identify an allogeneic donor was a problem for only
4 EA and 2 AA patients.Assessment of Participation in Clinical Trial, Survey, and
Biospecimen Research by Race among RPCI BMT Referrals
Table 1 shows the proportion of BMT referrals who
participated in any therapeutic clinical trial, survey, or bio-
specimen research by race. For clinical trial participation, EA
and AA rates were similar (62% and 57%, respectively),
whereas other minority groups had a lower participation
rate (13/30 or 43%). Table 4 summarizes the participation
rates in survey and biospecimen research by race for all RPCI
BMT referrals. Although minority groups were approached
more often (77% of AAs and 83% of other minorities)
than EAs (75%), the rate of consent was lower among
Figure 1. Patient Flow Chart.
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ities (64% consented of those approached) than among EAs
(81% consented of those approached). Further dropout
occurred among AAs and other minorities because only 34%
and 38%, respectively, of consented participants returned the
survey (epidemiologic questionnaire) comparedwith amuch
higher rate of return for EAs (70%). A very high proportion of
AAs provided a biospecimen (95%), which was identical to
the EA rate and higher than other minorities (88%). Only 19
minority patients participated in the survey and/or
biospecimen research; therefore, all minority groups are
combined together.Characteristics of Patients Who Did and Did Not
Participate in Survey Research
Of the 430 EAs and the 19 minority patients who
participated in survey research, there were signiﬁcantly
more minority than EA females (79% versus 44%, P ¼ .003)
(Table 5). Age, highest level of education, smoking history,
and employment status did not differ by race. Minorities
were more likely to have MM or amyloidosis (58% versus
26%, P> .05), to be single/never married (42% versus 13%, P¼
.003), and to be never drinkers (63% versus 35%, P> .05) than
EAs. Minorities had a signiﬁcantly lower number of peopleTable 3
Characteristics of All Patients Referred for a BMT Consultation at Roswell
Park Cancer Institute Who Did Not Receive a BMT, by Race
Reason for Not Receiving a BMT European
American
(N ¼ 470)
African
American
(N ¼ 38)
Other
(N ¼ 18)
Patient decision 96 (20) 5 (13) 1 (6)
Stable disease not requiring BMT 94 (20) 5 (13) 4 (22)
Died before BMT 88 (19) 6 (16) 3 (17)
Disease progression before BMT 67 (14) 0 2 (11)
Co-morbidities/physician decision 55 (12) 11 (29) 2 (11)
Transferred care to another center 41 (9) 5 (13) 4 (22)
Financial or insurance issues 15 (3) 0 0
Psychosocial or compliance concerns 9 (2) 4 (11) 0
No donor 4 (<1) 2 (5) 0
Age (too old for BMT) 1 (<1) 0 2 (11)supported by their household income than EAs (42% versus
17% supporting only 1 person in household, P ¼ .01), which
coincides with a higher rate of single/never married among
minorities. Minority household incomes were signiﬁcantly
less than EA household incomes (42% minorities versus 15%
EAs with <$25,000 annual income), which yields a median
annual household income per person in the household of
$10,417 for minority and $18,750 for EA households (P> .05).
Table 6 compares the characteristics of the survey re-
sponders versus nonresponders by race. Among EAs, non-
responders were more likely to be under 40 years and not
undergo a BMT, with little difference by gender and under-
lying diagnosis. Among AAs and other minority groups,
nonresponders were more likely to be male, under 40 years,
have leukemia, and not undergo a BMT. The higher rate of
responders among BMT patients is because this protocol is
part of the pre-BMTchecklist to ensure a high rate of patients
approached to consider enrollment. Non-BMT hematologic
malignancy services prioritize newly diagnosed patients are
approached, with pretreated patients having lower priority
for enrolling in the survey and biospecimen repository.
DISCUSSION
The seemingly low rate of BMT referrals and utilization of
BMTamongminorities reﬂects the underlying distribution of
minorities in the hematologic malignancy cases in the pri-
mary catchment area, indicating little to no disparity in re-
ferrals for transplant consultation. The higher proportion of
people younger than 30 years among minorities in the gen-
eral population compared with EAs infers that as the popu-
lation ages, the number of cancer cases in these minority
groups should increase. However, prior research has
demonstrated disparities in outcomes after BMT for minority
patients [8-14]; thus, efforts should focus on identifying
causes of worse outcomes in minorities and interventions to
reduce them.
Our ﬁndings are in contrast to a prior national study
using Surveillance, Epidemiology, and End Results inci-
dence rates applied to US Census Data to calculate the
annual number of new hematologic malignancy cases and
Center for International Blood and Marrow Transplant
Table 4
Proportion of BMT Referrals Who Were Approached, Consented and Participated in Survey or Biospecimen Research, by Race
Patients Referred for BMT EA N ¼ 1000 AA N ¼ 76 Other N ¼ 30 Total N ¼ 1106
N (%) approached by research staff of all BMT referrals 747 (75) 60 (77) 25 (83) 832 (75)
N (%) consented of those approached 606 (81) 38 (63) 16 (64) 660 (79)
N (%) returned survey of those consented 430 (70) 13 (34) 6 (38) 449 (68)
N (%) provided blood sample of those consented 575 (95) 36 (95) 14 (88) 625 (95)
N (%) returned survey & provided blood sample of those consented 410 (68) 13 (34) 10 (63) 433 (66)
Table 5
Characteristics of All Patients Referred for a BMT Consultation Who Participated in Survey Research
EA (N ¼ 430) n (%) Other (N ¼ 19) n (%) P-Value
Gender .003
Female 191 (44) 15 (79)
Male 239 (56) 4 (21)
Age, yr NS
20 7 (2) 0 (0)
21-39 54 (13) 1 (5)
40-64 295 (69) 14 (74)
65-74 71 (17) 4 (21)
75 3 (1) 0 (0)
Diagnosis NS
CLL/NHL 121 (28) 2 (11)
ALL/AML 113 (27) 2 (11)
MM/Amyloidosis 111 (26) 11 (58)
CML/MDS/MPN 54 (13) 3 (15)
HL 19 (4) 1 (5)
Benign hem. disorder 6 (1) 0 (0)
Solid tumor 6 (1) 0 (0)
Received BMT NS
Yes 298 (69) 11 (58)
No 117 (27) 6 (32)
Pending 15 (3) 2 (11)
Smoking status NS
Current 33 (8) 1 (5)
Former 202 (47) 8 (42)
Never 195 (45) 10 (53)
Alcohol consumption NS
Social 97 (23) 2 (11)
Monthly 82 (19) 3 (16)
Weekly 102 (24) 2 (11)
Never 149 (35) 12 (63)
Education level NS
High school or less 146 (34) 6 (32)
Some college 140 (33) 7 (37)
College graduate or more 144 (34) 6 (32)
Currently employed NS
No 246 (57) 12 (63)
Yes 184 (43) 7 (37)
Employment status NS
Full time 57 (13) 3 (16)
Part time 127 (30) 4 (21)
Unemployed 246 (57) 12 (63)
Number of people in household support by income
1 73 (17) 8 (42) .01
2 189 (44) 5 (26)
3 153 (36) 4 (21)
Missing 15 (3) 2 (11)
Total household annual income .01
<$25,000 65 (15) 8 (42)
$25-49,000 108 (25) 6 (32)
$50-75,000 99 (23) 2 (11)
>$75,000 101 (24) 0 (0)
Unknown 57 (13) 3 (16)
Median (range) household income per person in household $18,750 ($714-$75,000) $10,417 ($1,250-$37,500) NS
Marital status .003
Married 306 (71) 8 (42)
Separated/divorced 52 (12) 2 (11)
Single 54 (13) 8 (42)
Widowed 18 (4) 1 (5)
CLL indicates chronic lymphocytic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NS, not sig-
niﬁcant P > .05.
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Table 6
Comparison of Survey Responders Versus Non-Responders by Race
Patient Characteristic EA AA Other
Responder
N ¼ 430 n (%)
Non-Responder
N ¼ 570 n (%)
Responder
N ¼ 13 n (%)
Non-Responder
N ¼ 63 n (%)
Responder
N ¼ 6 n (%)
Non-Responder
N ¼ 24 n (%)
Male 239 (56) 338 (59) 3 (23) 30 (48) 1 (17) 13 (54)
Age, yr
<21 7 (2) 60 (11) 0 6 (10) 0 5 (21)
21-39 54 (13) 87 (15) 1 (8) 12 (19) 0 11 (46)
40-64 295 (69) 325 (57) 10 (77) 37 (59) 4 (67) 7 (29)
65-74 71 (17) 93 (16) 2 (15) 7 (11) 2 (33) 0
75 3 (1) 5 (1) 0 1 (2) 0 1 (4)
Diagnosis
Leukemia 139 (32) 220 (39) 1 (8) 25 (40) 3 (50) 11 (46)
NHL 106 (25) 145 (25) 1 (8) 7 (11) 0 3 (13)
MM 98 (23) 68 (12) 8 (62) 18 (29) 3 (50) 2 (8)
MDS 33 (8) 39 (7) 2 (15) 3 (5) 0 1 (4)
HL 19 (4) 34 (6) 1 (8) 3 (5) 0 1 (4)
MPN 10 (2) 19 (3) 0 1 (2) 0 2 (8)
Amyloidosis 13 (3) 14 (2) 0 1 (2) 0 1 (4)
Solid tumor 6 (1) 19 (3) 0 1 (2) 0 2 (8)
Benign hem. disorder 6 (1) 12 (2) 0 4 (6) 0 1 (4)
Decision regarding BMT
Yes 298 (69) 196 (34) 8 (62) 23 (37) 3 (50) 7 (29)
No 117 (27) 353 (62) 3 (23) 35 (56) 3 (50) 15 (63)
Pending 15 (3) 21 (4) 2 (15) 5 (8) 0 2 (8)
EA indicates European American; AA, African American; Other, all other races and ethnicities.
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gous, 50% of related allogeneic, and >90% of unrelated
allogeneic BMT to estimate the number of autologous and
allogeneic BMTs performed in the United States [2].
Although this study, by Joshua et al., reported signiﬁcantly
fewer BMTs for AAs and women, we found the proportion
of AAs who received a BMT was similar to the proportion
of AAs diagnosed with a hematologic malignancy and the
general adult population in the catchment area. Although
our study was conﬁned to a smaller geographic area, we
captured >95% of hematologic malignancy cases, 100% of
BMT referrals, and 100% of BMTs performed in this area. It
is unknown if the difference in results between these 2
studies is because (1) our catchment area was different
from the rest of the United States; (2) we had complete
ascertainment of referrals and BMTs; (3) we restricted our
study to adults, whereas Joshua et al. [2] included pediatric
cases; or (4) our study is more contemporaneous (2005 to
2011) than Joshua et al.’s (1997 to 2002) and racial dis-
parities have decreased recently.
We found results similar to others [15] that EAs are more
likely than AAs to participate in survey research; however, to
our knowledge this is the ﬁrst report of similar rates of
participation for biospecimen research by race. The low
participation rate in survey research could be due to how a
patient is approached and consented, a racial (mis)match
between consenter and patient, or how often a patient is
approached to participate. In addition, the structure and
length of our survey (45 to 47 pages) may deter patients from
participating in or comprehending the survey itself. How-
ever, we have no information on patients who did not
participate or return the survey to understand causes of the
differential participation rate.
There are several limitations to our population-based
study design. Three independent sources of data (US
Census, NYSPACED, and RPCI BMT database) are not
harmonized in the reporting of age groups (US Census  18
years and NYSPACED  20 years) and race/ethnicity (self-
report versus medical record). Although 75% of our referralsderive from a limited geographic area (8 contiguous
counties), the remainder are distributed across a wider
catchment area, making it difﬁcult to measure referral rates
by race/ethnicity from those regions. It is disappointing that
less than half of our referrals participated in survey or bio-
specimen research, and we are unable to determine reasons
why most declined participation (actively or passively).
Previous research describes 4 factors that have demon-
strated improvement in minority recruitment and retention
in health-related research: targeted/tailored sampling
approach and identiﬁcation of eligible participants, com-
munity involvement and timing of contact, incentives and
logistical issues, and cultural adaptations for research
participation [15-17]. Thus, a more targeted approach to
recruitment of minority subjects in survey research may
yield a better response rate.ACKNOWLEDGMENTS
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